Show Summary Details
Page of

Biomarkers Predicting Antidepressant Treatment Response: An Overview 

Biomarkers Predicting Antidepressant Treatment Response: An Overview
Biomarkers Predicting Antidepressant Treatment Response: An Overview

Bharathi S. Gadad

, Manish K. Jha

, and Madhukar H. Trivedi

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 May 2022

In clinical practice, patients do not always experience symptomatic remission or treatment response, even after trying various types of antidepressant medications. To improve outcomes and reduce attrition and nonadherence, there is a great need for personalized treatment of major depression. Hence, recent research efforts have focused on the identification of biological markers (or biomarkers) that can predict whether an individual patient will respond to the commonly used antidepressants. In this chapter, we review the biomarkers associated with antidepressant treatment response with particular attention to genetic, proteomic, metabolomic, transcriptomic, epigenetic biological, and biochemical markers. Although the “omics” approach holds great promise for the future, challenges and roadblocks for future research will need to be addressed.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.